Compare Stocks: ASLN, CVKD, GLMD, and GRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASLN ASLAN Pharmaceuticals	$0.60	$0.60	$0.48 ▼ $25.44	$1.23M	1.4	122,322 shs	N/A
CVKD Cadrenal Therapeutics	$1.33 +0.4%	$1.64	$1.00 ▼ $14.64	$4.72M	1.82	187,873 shs	70,129 shs
GLMD Galmed Pharmaceuticals	$4.59 -0.9%	$4.39	$3.29 ▼ $13.20	$4.78M	0.67	52,894 shs	302,067 shs
GRI GRI Bio	$2.04 -5.3%	$1.79	$1.36 ▼ $64.12	$4.45M	-1.24	269,951 shs	13,147 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASLN ASLAN Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CVKD Cadrenal Therapeutics	+17.86%	+22.22%	-15.92%	-53.85%	-90.35%
GLMD Galmed Pharmaceuticals	0.00%	0.00%	+13.33%	+0.04%	-60.97%
GRI GRI Bio	+4.88%	+18.78%	+20.11%	+9.69%	-96.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASLN ASLAN Pharmaceuticals	$0.60	$0.60	$0.48 ▼ $25.44	$1.23M	1.4	122,322 shs	N/A
CVKD Cadrenal Therapeutics	$1.33 +0.4%	$1.64	$1.00 ▼ $14.64	$4.72M	1.82	187,873 shs	70,129 shs
GLMD Galmed Pharmaceuticals	$4.59 -0.9%	$4.39	$3.29 ▼ $13.20	$4.78M	0.67	52,894 shs	302,067 shs
GRI GRI Bio	$2.04 -5.3%	$1.79	$1.36 ▼ $64.12	$4.45M	-1.24	269,951 shs	13,147 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASLN ASLAN Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CVKD Cadrenal Therapeutics	+17.86%	+22.22%	-15.92%	-53.85%	-90.35%
GLMD Galmed Pharmaceuticals	0.00%	0.00%	+13.33%	+0.04%	-60.97%
GRI GRI Bio	+4.88%	+18.78%	+20.11%	+9.69%	-96.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASLN ASLAN Pharmaceuticals	0.00	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	881.13% Upside
GLMD Galmed Pharmaceuticals	1.00	Sell	N/A	N/A
GRI GRI Bio	2.33	Hold	$21.00	931.94% Upside

Current Analyst Ratings Breakdown

Latest ASLN, CVKD, GLMD, and GRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
7/17/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GLMD Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GRI GRI Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASLN ASLAN Pharmaceuticals	$12M	0.10	N/A	N/A	($6.50) per share	-0.09
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$23.04 per share	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	$4.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASLN ASLAN Pharmaceuticals	-$44.22M	-$21.92	N/A	N/A	N/A	N/A	-8,454.87%	-121.60%	N/A
CVKD Cadrenal Therapeutics	-$13.24M	-$4.90	N/A	N/A	N/A	N/A	-406.41%	-273.80%	11/9/2026 (Estimated)
GLMD Galmed Pharmaceuticals	-$10.31M	-$15.18	N/A	N/A	N/A	N/A	-73.68%	-60.88%	11/25/2026 (Estimated)
GRI GRI Bio	-$11.96M	-$38.37	N/A	N/A	N/A	N/A	-134.03%	-106.83%	11/13/2026 (Estimated)

Latest ASLN, CVKD, GLMD, and GRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2026	GLMD Galmed Pharmaceuticals	-$3.12	-$2.86	+$0.26	-$2.86	N/A	N/A
8/14/2026	Q2 2026	GRI GRI Bio	-$1.19	-$0.91	+$0.28	-$0.91	N/A	N/A
8/13/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	-$1.14	+$0.28	-$1.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	$1.91	93.86%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASLN ASLAN Pharmaceuticals	N/A	1.05	1.05
CVKD Cadrenal Therapeutics	N/A	3.73	3.73
GLMD Galmed Pharmaceuticals	N/A	4.16	4.16
GRI GRI Bio	N/A	10.30	10.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASLN ASLAN Pharmaceuticals	58.82%
CVKD Cadrenal Therapeutics	7.92%
GLMD Galmed Pharmaceuticals	76.14%
GRI GRI Bio	33.95%

Insider Ownership

Company	Insider Ownership
ASLN ASLAN Pharmaceuticals	4.69%
CVKD Cadrenal Therapeutics	14.59%
GLMD Galmed Pharmaceuticals	19.80%
GRI GRI Bio	8.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASLN ASLAN Pharmaceuticals	30	2.04 million	1.95 million	No Data
CVKD Cadrenal Therapeutics	5	3.57 million	3.05 million	Not Optionable
GLMD Galmed Pharmaceuticals	20	1.04 million	836,000	Not Optionable
GRI GRI Bio	5	2.19 million	2.00 million	Not Optionable

ASLN, CVKD, GLMD, and GRI Headlines

Recent News About These Companies

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

September 14, 2026 | zacks.com

UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy

September 14, 2026 | benzinga.com

HC Wainwright Analysts Raise Earnings Estimates for GRI Bio

September 14, 2026 | americanbankingnews.com

GRI Bio Plans 52-Week Study Of GRI-0621 Following Phase 2a IPF Data

September 8, 2026 | rttnews.com

GRI Bio Reports Phase 2a Data Showing Repair Phenotype and FVC Improvement with GRI-0621 in Idiopathic Pulmonary Fibrosis

September 8, 2026 | quiverquant.comQ

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

September 8, 2026 | globenewswire.com

GRI Bio Featured in "Why Now" On-Demand Video Webcast

August 27, 2026 | globenewswire.com

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

August 24, 2026 | globenewswire.com

Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks

August 20, 2026 | nypost.comN

Banner Bank Releases New Corporate Responsibility Report

July 14, 2026 | gurufocus.com

GRI Bio Inc. (GRI) Holds Steady Near Key Support at $1.77 - Volatility Surface

July 14, 2026 | donanimhaber.comD

GRI Bio Inc.

June 26, 2026 | marketwatch.com

GRI Bio Secures FDA Orphan Drug Status for IPF

June 18, 2026 | tipranks.com

GRI Bio, Inc.: GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

June 18, 2026 | finanznachrichten.de

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

June 18, 2026 | globenewswire.com

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

May 18, 2026 | markets.businessinsider.com

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 18, 2026 | globenewswire.com

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued ...

May 14, 2026 | markets.businessinsider.com

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

May 14, 2026 | globenewswire.com

GRI Bio (GRI) price target decreased by 75.16% to 163.20

April 9, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ASLN, CVKD, GLMD, and GRI Company Descriptions

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)

As of 09/23/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Cadrenal Therapeutics NASDAQ:CVKD

$1.32 +0.01 (+0.38%)

As of 11:44 AM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Galmed Pharmaceuticals NASDAQ:GLMD

$4.59 -0.04 (-0.86%)

Closing price 09/9/2026

Extended Trading

$4.59 0.00 (0.00%)

As of 09/9/2026 07:56 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GRI Bio NASDAQ:GRI

$2.04 -0.12 (-5.35%)

As of 11:43 AM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASLN, CVKD, GLMD, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASLN, CVKD, GLMD, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASLN, CVKD, GLMD, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ASLN, CVKD, GLMD, and GRI Company Descriptions

ASLAN Pharmaceuticals NASDAQ:ASLN

Cadrenal Therapeutics NASDAQ:CVKD

Galmed Pharmaceuticals NASDAQ:GLMD

GRI Bio NASDAQ:GRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASLN, CVKD, GLMD, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASLN, CVKD, GLMD, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASLN, CVKD, GLMD, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ASLN, CVKD, GLMD, and GRI Company Descriptions

ASLAN Pharmaceuticals NASDAQ:ASLN

Cadrenal Therapeutics NASDAQ:CVKD

Galmed Pharmaceuticals NASDAQ:GLMD

GRI Bio NASDAQ:GRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools